OBJECTIVE: To evaluate the efficacy and safety of intraprostatic injection of Chuanshentong in the treatment of chronic abacterial prostatitis/chronic pelvic pain syndrome(CAP/CPPS). METHODS: Randomized, double blinded, placebo controlled trials were carried out from September 2002 to March 2003. A total of 38 patients with diagnosed CAP/CPPS, 24 experimental and 14 controls, were analyzed. In the trial group, 6 ml of mixed solution of Chuanshentong and lidocaine was transperineally injected into one lobe of the prostate, once a day for 6 days. Likewise, the control group was treated with placebo containing lidocaine. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index(CPSI) after a 6-week follow-up. The main semen parameters before and after 3-month treatment were compared. RESULTS: In the trial group, 13 cases (56.5%) were completely cured, 5 cases(21.7%) showed remarkable effect, and 4 cases (17.4%) were improved. While in the control group, effectiveness was shown in only 2 cases (15.4%), and improvement in 3 cases (23%). CPSI scores decreased significantly after treatment(95% of confidence interval: 17.97-23.08). Chuanshentong solution had no obvious impact on the main semen parameters. No severe adverse effects were observed. CONCLUSION: Transperineal intraprostatic injection of Chuanshentong is a safe and effective method for the treatment of CAP/CPPS.
RCT Entities:
OBJECTIVE: To evaluate the efficacy and safety of intraprostatic injection of Chuanshentong in the treatment of chronic abacterial prostatitis/chronic pelvic pain syndrome(CAP/CPPS). METHODS: Randomized, double blinded, placebo controlled trials were carried out from September 2002 to March 2003. A total of 38 patients with diagnosed CAP/CPPS, 24 experimental and 14 controls, were analyzed. In the trial group, 6 ml of mixed solution of Chuanshentong and lidocaine was transperineally injected into one lobe of the prostate, once a day for 6 days. Likewise, the control group was treated with placebo containing lidocaine. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index(CPSI) after a 6-week follow-up. The main semen parameters before and after 3-month treatment were compared. RESULTS: In the trial group, 13 cases (56.5%) were completely cured, 5 cases(21.7%) showed remarkable effect, and 4 cases (17.4%) were improved. While in the control group, effectiveness was shown in only 2 cases (15.4%), and improvement in 3 cases (23%). CPSI scores decreased significantly after treatment(95% of confidence interval: 17.97-23.08). Chuanshentong solution had no obvious impact on the main semen parameters. No severe adverse effects were observed. CONCLUSION: Transperineal intraprostatic injection of Chuanshentong is a safe and effective method for the treatment of CAP/CPPS.